BioSpace News Archive

Bringing new drugs to the market costs billions of dollars. It could not be done without investments by both the NIH and biopharma companies.

In a Phase I trial, Caribou’s allogeneic CAR-T cell therapy candidate induced high rates of treatment response in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

A new report by the U.S. Government Accountability Office finds that despite the promise of regenerative medicine technologies they are held back by regulatory and manufacturing challenges.

The Swiss pharma is in talks to acquire Roivant Sciences’ RVT-3101, an anti-TL1A antibody that recently showed promising results in a Phase IIb ulcerative colitis trial, reports The Wall Street Journal.

This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act

Eli Lilly said Friday it plans to pay up to $1.925 billion to acquire Versanis and its lead asset, bimagrumab, a monoclonal antibody that aims to reduce fat mass without affecting muscle mass.

RaySearch Laboratories AB announces the release of the latest version of RayCare®*, the next generation oncology information system.

Centogene N.V. announced that it has received notifications from the Nasdaq Stock Market LLC Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450 and with the minimum Market Value of Publicly Held Shares requirement for continued listing on the Nasdaq under Nasdaq Listing Rules 5450.

Korro Bio, Inc. and Frequency Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking place in Orlando, Florida from July 20-23.